Vega Investment Solutions Invests $709,000 in IQVIA Holdings Inc. $IQV

Vega Investment Solutions purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,671 shares of the medical research company’s stock, valued at approximately $709,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Financial Freedom LLC acquired a new position in IQVIA in the first quarter worth $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $27,000. Compass Financial Management LLC bought a new position in shares of IQVIA in the second quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at about $27,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQVIA stock opened at $260.30 on Tuesday. The company has a market cap of $42.85 billion, a PE ratio of 32.30, a PEG ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $261.88. The company’s 50-day moving average is $214.97 and its two-hundred day moving average is $187.62.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last three months. Insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of a number of research analyst reports. Stifel Nicolaus increased their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. TD Cowen boosted their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.